Key Points - A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. - Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges. Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are…
Continue reading...